Journal of military, veteran and family health · 2023
Efficacy and safety of CounterFlow in animal models of hemorrhage.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Nuoya, Yeh Han H, Khavari Adele, Zhang-Gao Han, Tenn Catherine, Semple Hugh A, Cau Massimo F, Beckett Andrew, Kastrup Christian J
Аннотация
INTRODUCTION: Hemorrhage is a major cause of battlefield mortality, contributing to 91% of potentially survivable combat-related deaths. Death from hemorrhage often occurs in pre-hospital settings, and more efficacious hemorrhage control interventions are needed to extend survival and enable casualties to reach definitive surgery. CounterFlow is a novel topical hemostatic agent that uses self-propelling particles to deliver thrombin and tranexamic acid against active bleeding. It achieves and maintains hemostasis at the site of injury through a combination of mechanical, biological, and chemical effects.
METHODS: All literature in which CounterFlow was tested in animal models of hemorrhage was reviewed to compile its preclinical safety and efficacy as a hemostatic agent.
RESULTS: CounterFlow extended survival and halted hemorrhage in multiple animal models that mimicked common and deadly injuries encountered in military and civilian settings, including junctional wounds, surgical bleeding, non-compressible intra-abdominal hemorrhage, and upper gastrointestinal bleeding. Thromboembolism, tissue damage, and toxicity were not observed.
DISCUSSION: This narrative review discusses the animal models that have been used to investigate CounterFlow as a hemostatic agent for pre-hospital hemorrhage control. Future directions and potential expansion for civilian use are also considered.
METHODS: All literature in which CounterFlow was tested in animal models of hemorrhage was reviewed to compile its preclinical safety and efficacy as a hemostatic agent.
RESULTS: CounterFlow extended survival and halted hemorrhage in multiple animal models that mimicked common and deadly injuries encountered in military and civilian settings, including junctional wounds, surgical bleeding, non-compressible intra-abdominal hemorrhage, and upper gastrointestinal bleeding. Thromboembolism, tissue damage, and toxicity were not observed.
DISCUSSION: This narrative review discusses the animal models that have been used to investigate CounterFlow as a hemostatic agent for pre-hospital hemorrhage control. Future directions and potential expansion for civilian use are also considered.